In addition, the uveal melanoma subtype usually lacks BRAF mutations (Edmunds et al, 2003; Rimoldi et al, 2003), and with the exception of selumetinib, few data exist supporting the use of BRAF or MEK inhibitors in uveal melanoma (Carvajal et al, 2014). This evidence concerns the gene MAP2K7 and uveal melanoma.